Antihypertensiva

(Klinische Pharmakologie und therapeutische Anwendung)
  • H. Knauf
  • K. O. Stumpe
  • R. Kolloch
  • A. Overlack
  • W. Rascher
  • D. Ganten
  • R. E. Lang
  • Th. Unger

Zusammenfassung

Diuretika stellen heute eine wertvolle Stoffklasse in der Pharmakotherapie dar. Dies gilt nicht nur für die Korrektur von Störungen des Salz- und Wasserhaushalts, insbesondere die Therapie von Ödemkrankheiten; sie spielen auch bei nichtödematösen Erkrankungen wie der Hypertonie eine wichtige therapeutische Rolle.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abshagen U, Besenfelder E, Enderle R, Koch K, Neubert B (1979) Kinetics of canrenone after single and multiple doses of spironolactone. Europ J Pharmacol 16: 255CrossRefGoogle Scholar
  2. 2.
    Beermann B, Groschinsky-Grind M (1977) Pharmacokinetics of hydrochlorothiazide in man. Europ J clin Pharmacol 12: 297CrossRefGoogle Scholar
  3. 3.
    Benet LZ (1979) Pharmacokinetics, pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm 7: 1PubMedCrossRefGoogle Scholar
  4. 4.
    Biamino G, Wessel HJ, Nöring J, Schröder R (1975) Plethysmographische und In-vitro-Untersuchungen über die vasodilatorische Wirkung von Furosemid (Lasix). Int J Clin Pharmacol Ther Toxicoll 2: 356Google Scholar
  5. 5.
    Burg MB (1977) The action of diuretics in the isolated tubule preparation. In: Siegenthaler W (ed) Diuretics in research and clinics. Thieme, Stuttgart, S 30–35Google Scholar
  6. 6.
    Burg MB, Cardinal J, Green N (1973) Furosemide effect on the isolated perfused tubules. Am J Physiol 225: 119PubMedGoogle Scholar
  7. 7.
    Bumheim C, Münzesheimer C, Rabon E, Sachs G (1982), Ion pathways in renal brush border membranes. Biochim Biophys Acta 685: 260CrossRefGoogle Scholar
  8. 8.
    Cannon PJ, Heinemann H, Stason WP (1965) Ethacrynic acid. Effectivness and mode of action in man. Circulation 31: 5PubMedGoogle Scholar
  9. 9.
    Constanzo LS, Windhager EE (1978) Calcium and sodium transport by the distal convoluted tubule of the rat. Am J Physiol 4: F492Google Scholar
  10. 10.
    Cuthbert AW, Fanelli GM, Scriabine A (1979) Amiloride and epithelial sodium transport. Urban & Schwarzenberg, MünchenGoogle Scholar
  11. 11.
    Daviddow M, Gavrilovich L, Mroczek W, Finnerty FA (1969) Relation of extracellular fluid volume to arterial pressure during drug-induced saluresis. Circulation 40: 349Google Scholar
  12. 12.
    Davies DL, Wilson GM (1975) Diuretics: Mechanism of action and clinical application. Drugs 9: 178PubMedCrossRefGoogle Scholar
  13. 13.
    Dettli L (1977) Elimination kinetics and dosage adjustment of drugs in patients with kidney disease. Prog Pharmacol 1: 4Google Scholar
  14. 14.
    Diskhit K, Vyden JK, Forrester JS, Chatterjée K, Prakash R, Swan HJS (1973) Renal and extra-renal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 288: 1087CrossRefGoogle Scholar
  15. 15.
    Duarte LG, Chomety F, Giebisch G (1971) Effect of amiloride, ouabain and furosemide on distal tubular function in the rat. Am J Physiol 221: 632PubMedGoogle Scholar
  16. 16.
    Farman N, Vandenwalle A, Bonvalet JP (1982) Binding sites of mineralo and glucocorticoids along the mammalian nephron (rabbit and rat). In: Morel F (ed) Biochemistry of kidney function. Elsevier, Amsterdam S 285Google Scholar
  17. 17.
    George CF (1980) Amiloride handling in renal failure. Br J Clin Pharmacol 9: 94PubMedGoogle Scholar
  18. 18.
    Good DW, Wright FS (1979) Luminal influences on potassium secretion: sodium concentration and fluid flow rate. Am J Physiol 236: F192PubMedGoogle Scholar
  19. 19.
    Greven J, Heidenreich O (1978) Effects of ozolinone, a diuretic active metabolite of etozoline, on renal function. I. Clearance studies in dogs. Naunyn Schmiedebergs Arch Pharmacol 304: 283PubMedCrossRefGoogle Scholar
  20. 20.
    Greven J, Beckers M, Defrain W, Maywald K, Heidenreich O (1980) Studies with the optically active isomers of the new diuretic drug ozolinone. II. Inhbition by d-ozolinone of furosemideinduced diuresis. Pflugers Arch 384: 61PubMedCrossRefGoogle Scholar
  21. 21.
    Greven J, Defrain W, Glaser K, Maywald K, Heidenreich O (1980) Studies with the optically active isomers of the new diuretic drug ozolinone. I. Differences in stereoselectivity of the renal target structures of ozolinone. Pflugers Arch 384: 57PubMedCrossRefGoogle Scholar
  22. 22.
    Guignard JP, Peters G (1970) Effects of triamterene and amiloride on urinary acidification and potassium excretion. Eur J Pharmacol 10: 255PubMedCrossRefGoogle Scholar
  23. 23.
    Hansen LL, Schilling AR, Wiederholt M (1981) Effect of calcium, furosemide and chlorothiazide on net volume reabsorption and basolateral membrane potential in the distal tubule. Pflügers Arch 389: 121PubMedCrossRefGoogle Scholar
  24. 24.
    Heidenreich O, Fülgraff G (1975) Niere und Elektrolyte. In: Forth W, Henschler D, Rummel W (Hrsg) Pharmakologie und Toxikologie. Wissenschaftsverlag, S 226Google Scholar
  25. 25.
    Heinz E, Geck P (1980) Coupling of ion flows in cell suspension systems. Ann N Y Acad Sci 341: 57PubMedCrossRefGoogle Scholar
  26. 26.
    Hummerich W, Krause DK, Konrads A, Kaufmann W (1980) Die Bedeutung von Volumfaktoren und neuralen Mechanismen bei der Reninfreisetzung nach Furosemid und Etacrynsäure. In: Krück F, Schrey A (Hrsg) Diuretika. Springer, Berlin Heidelberg New York, S 123Google Scholar
  27. 27.
    Joos L, Kewitz H (1980) Erhöhung der „Very Low Density Lipoproteine (VLDL) im Plasma gesunder Männer während der Behandlung mit Diuretika. In: Krück F, Schrey A (Hrsg) Diuretika. Springer, Berlin Heidelberg New York, S 135Google Scholar
  28. 28.
    Jørgenson PL (1975) The function of Na+ : K+ ATPase in the thick ascending limb of Henle’s loop. Q Rev Biophys 7: 239CrossRefGoogle Scholar
  29. 29.
    Kassirer JT, Harrington JT (1977) Diuretics and potassium metabolism: A reassessment of the need, effectiveness and safety of potassium therapy. Kidney Int 11: 505PubMedCrossRefGoogle Scholar
  30. 30.
    Keller E, Hoppe-Seyler G, Knauf H, Schollmeyer P (1980) Pharmakokinetik and Pharmakodynamik von Furosemid bei Normalpersonen, Leberzirrhose mit Aszites und terminaler Niereninsuffizienz. Verh Dtsch Ges Inn Med 86: 1257Google Scholar
  31. 31.
    Knauf H (1976) Kaliumsparer: Einseitige Diuretika, aber ideale Kombinationspartner. Therapiewoche 26: 5384Google Scholar
  32. 32.
    Knauf H, Lübcke R (1975) Evidence for Na+ independent active secretion of K+ and HCO3 by rat salivary duct epithelium. Pflügers Arch 361: 55PubMedCrossRefGoogle Scholar
  33. 33.
    Knauf H, Mutschier E (1980) Pharmakokinetik von Diuretika bei eingeschränkter Nierenfunktion. In: Krück F, Schrey A (Hrsg) Diuretika. Springer, Berlin Heidelberg New York, S 14Google Scholar
  34. 34.
    Knauf H, Mutschier E (1982) Der Einfluß von Erkrankungen der Nieren oder der Leber auf die Pharmakokinetik von Diuretika. In: Krück F, Schrey A (Hrsg) Diuretika. Wolf, MünchenGoogle Scholar
  35. 35.
    Knauf H, Wais U, Lübcke R, Albiez G (1976) On the mechanism of action of triamterene. Effects on transport of Na+, K+, and H+/HCO3 ions. Eur J Clin Invest 6: 43PubMedCrossRefGoogle Scholar
  36. 36.
    Knauf H, Mutschier E, Völger KD, Wais U (1978) Pharmakologische Wirksamkeit von Phase-I-und Phase-II-Metaboliten des Triamteren. Arzneimittelforsch 28: 1417PubMedGoogle Scholar
  37. 37.
    Knauf H, Hasenfuss G, Wais U, Schollmeyer P (1980) Independence of etozolin elimination of kidney function. Arzneimittelforsch 30: 1791PubMedGoogle Scholar
  38. 38.
    Knauf H, Liebig R, Schollmeyer P, Kölle EU, Mutschier E (1983) Parmacodynamics and Kinetics of Etozolin in Patients with Renal Insufficiency Europ J clin Pharmacol in pressGoogle Scholar
  39. 39.
    Knauf H. Lübcke R, Kreutz W, Sachs G (1982) Interrelationships of ion transport in rat sub-maxillary duct epithelium. Am J Physiol 242: F132PubMedGoogle Scholar
  40. 40.
    Knauf H, Möhrke W, Mutschier E (1983) Delayed elimination of triamterene and its active metabolite in chronic renal failure. Europ J clin Pharmacol 24: 153CrossRefGoogle Scholar
  41. 41.
    Knauf H, Schollmeyer P, Sobel M, Mutschler E (1983) Pharmacodynamics and Kinetics of Xipamide in Renal Failure Europ J. Clin. Pharmacol. in pressGoogle Scholar
  42. 42.
    Kramer HJ, Stinnesbeck B, Prior W, Düsing R (1980) Interaktion zwischen Diuretika und renalem Prostaglandinsystem. In: Krück F, Schrey A (Hrsg) Diuretika. Springer, Berlin Heidelberg New York, S 64Google Scholar
  43. 43.
    Laragh JH, Heinemann HO, Demartini FE (1958) Effect of chlorothiazide on electrolyte transport in man. JAMA 166: 145Google Scholar
  44. 44.
    Lehmann K (1965) Trennung, Isolierung und Identifizierung von Stoffwechselprodukten des Triamterens. Arzneimittelforsch 15: 812PubMedGoogle Scholar
  45. 45.
    Leilich G, Knauf H, Mutschler E, Völger KD (1980) Ausscheidung von mono-und bivalenten Kationen im Rattenharn nach Applikation von Triamteren und seinem Phase-II-Metaboliten. Magnesium Bull 1: 8Google Scholar
  46. 46.
    Loreaux L, Menard R, Taylor A, Patpita JL, Santen R (1976) Spironolactone and endocrine dysfunction. Ann Intern Med 85: 630Google Scholar
  47. 47.
    Lund-Johansen P (1970) Hemodynamic changes in long-term diuretic therapy of essential hypertension. Acta Med scand 187: 509PubMedCrossRefGoogle Scholar
  48. 48.
    Mallette LE (1977) Acetazolamide-accelerated anticonvulsant osteomalacia. Arch Intern Med 137: 1013PubMedCrossRefGoogle Scholar
  49. 49.
    Manuel MA, Beirne GJ, Wagnaild JT, Weiner MW (1974) An effect of spironolactone on urinary acidification in normal man. Arch Intern Med 134: 472PubMedCrossRefGoogle Scholar
  50. 50.
    Mendlowitz M, Naftchi N, Gitlow SE (1960) The effect of chlorothiazide and its congeners on the digital circulation in normotensive subjects and in patients with essential hypertension. Ann NY Acad Sci 88: 964PubMedCrossRefGoogle Scholar
  51. 51.
    Meng K, Loew D (1974) Diuretika. Thieme, StuttgartGoogle Scholar
  52. 52.
    Mueller A, Steinmetz PR (1978) Spironolactone: An aldosterone agonist in the stimulation of H+ secretion by turtle urinary bladder. J Clin Invest 58: 351Google Scholar
  53. 53.
    Murer H, Hopfer U, Kinne R (1976) Sodium/proton antiport in brush-border membrane vesicles isolated from rat small intestine and kidney. Biochem J 154: 597PubMedGoogle Scholar
  54. 54.
    Muschaweck R, Hajdú P (1964) Die salidiuretische Wirksamkeit der Chlor-N-(2-furyl-methyl)-5-sulfanyl-anthranilsäure. Arzneimittelforsch 14: 44PubMedGoogle Scholar
  55. 55.
    Niemeyer C, Hasenfuß G, Wais U, Knauf H, Schäfer-Korting M, Mutschler E (1983) Pharmacokinetics of hydrochlorothiazide in relation to renal function. Europ J clin PharmacolGoogle Scholar
  56. 56.
    Overlack A, Stumpe KO, Ressel C, Krück F (1979) Defekt im intrarenalen Kallikrein-Kinin-System und Blutdrucksenkung nach oralem Kallikrein bei essentieller Hypertension. Verh Dtsch Ges Inn Med 69Google Scholar
  57. 57.
    Patak RV, Mookerjee BK, Bentzel CJ, Hysert PE, Babej M, Lee JB (1975) Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins 10: 649PubMedCrossRefGoogle Scholar
  58. 58.
    Sadée W, Dagcioglu M, Schröder R (1973) Pharmacokinetics of spironolactone, canrenone and canrenone-K in humans. J Pharmacol Exp Ther 185: 686PubMedGoogle Scholar
  59. 59.
    Sadée W, Abshagen U, Finn C, Rietbrock N (1974) Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats. Naunyn Schmiedebergs Arch Pharmacol 283–303Google Scholar
  60. 60.
    Satzinger G (1977) Struktur-Aktivitätsbetrachtungen zu Etozolin, einem neuartigen Diuretikum. Arzneimittelforsch 27: 1742PubMedGoogle Scholar
  61. 61.
    Schmidt U, Dubach UL (1970) The behavior of Na+ : K+-ATPase in various structures of the rat nephron after furosemide application. Nephron 7: 447PubMedCrossRefGoogle Scholar
  62. 62.
    Schmidt U, Schmid J, Dubach UL (1975) Sodium- and potassium-activated ATPase. A possible target of aldosterone. J Clin Invest 55: 655PubMedCrossRefGoogle Scholar
  63. 63.
    Stason WB, Cannon PJ, Heinemann HO (1966) Furosemide, a clinical evaluation of its diuretic action. Circulation 34: 910PubMedGoogle Scholar
  64. 64.
    Stolte H, Lustenberger N, Schurek HJ (1977) Zur Differentialtherapie mit Diuretika bei akuten und chronischen Erkrankungen. In: Hierholzer K, Rietbrock N (Hrsg) Physiologische und pharmakologische Grundlagen der Therapie. Straube, Erlangen, S 91Google Scholar
  65. 65.
    Tarazi RC, Dustan HP, Frohlich ED (1970) Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation 41: 709PubMedGoogle Scholar
  66. 66.
    Thurau K (1977) Diuretics and tubuloglomerular feedback regulation of GFR. In: Siegenthaler W et al. (eds) Diuretics in research and climcs. Thieme, Stuttgart, S 43Google Scholar
  67. 67.
    Vollmer KO, Hodenberg A von, Poisson A, Gladigau V, Hengy H (1977) Resorption, Verteilung, Metabolismus und Ausscheidung von 14C-Etozolin bei Ratte, Hund und Mensch. Arzneimittelforsch 27: 1767PubMedGoogle Scholar
  68. 68.
    Weidmann P (1980) Recent pathogenetic aspects in essential hypertension and hypertension associated with diabetes mellitus. Klin Wochenschr 58: 1971Google Scholar
  69. 69.
    Weinmann EJ, Eknoyan G, Suki WN (1975) The influence of extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest 55: 283CrossRefGoogle Scholar
  70. 70.
    Wright FS, Schnermann J (1974) Interference with feedback control of glomerular filtration rate by furosemide, triflocin, and cyanide. J Clin Invest 53: 1695PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Aberg H (1974) Beta receptors and renin release. N Engl J Med 290: 1026PubMedGoogle Scholar
  2. 2.
    Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153: 586–591PubMedGoogle Scholar
  3. 3.
    Amery A, Billiet L, Fagard R (1974) Beta receptors and renin release. N Engl J Med 290: 284PubMedGoogle Scholar
  4. 4.
    Barritt DW, Marshall AJ (1977) Treating hypertension. The place of beta blockade. Br Heart J 39: 821–824PubMedCrossRefGoogle Scholar
  5. 5.
    Birkenhäger WH, De Leeuw PW, Wester A, Kho TL, Vandongen R, Falke HE (1977) Therapeutic effects of β-adrenoreceptor blocking agents in hypertension. In: Frick P, Harnack G-A von, Martini GA, Prader A, Schoen R, Wolff HP (Hrsg) Ergebnisse der Inneren Medizin und Kinderheilkunde, Bd 39. Springer, Berlin Heidelberg New York, S 117–134CrossRefGoogle Scholar
  6. 6.
    Bravo EL, Tarazi RC, Dustan HP (1974) On the mechanism of suppressed plasma renin activity during beta-adrenergic blockade with propranolol. J Lab Clin Med 83: 119–128PubMedGoogle Scholar
  7. 7.
    Bühler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR (1972) Propranolol inhibition of renin-secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 287: 1209–1214PubMedCrossRefGoogle Scholar
  8. 8.
    Carruthers SG, Kelly JG, McDevitt DG, Shanks RG (1974) Blood levels of practolol and oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther 15: 497PubMedGoogle Scholar
  9. 9.
    England JDF, Simons LA, Gibson JC, Carlton M (1980) The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clin Exp Pharmacol 7: 329–333CrossRefGoogle Scholar
  10. 10.
    Frishman W (1979) Clinical pharmacology of the new betaadrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J 97: 663–670PubMedCrossRefGoogle Scholar
  11. 11.
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 62: 707–714PubMedCrossRefGoogle Scholar
  12. 12.
    Greenblatt DJ, Koch-Weser J (1978) Clinical toxicity of propranolol and practolol. A report from the Boston Collaborative Drug Surveillance Program. In: Avery G (ed) Cardiovasc drugs, II. Baltimore University Park Press, Baltimore, pp 179–195Google Scholar
  13. 13.
    Heck I, Trübestein G, Stumpe KO (1981) Effects of combined α- and β-receptor blockade on peripheral circulation in essential hypertension. Clin Sci 61: 429s–432sPubMedGoogle Scholar
  14. 14.
    Helgeland A, Hjerman I, Leren P, Enger S, Holme I (1978) High-density lipoprotein, cholesterol and antihypertensive drugs. The Oslo study. Br Med J 2: 403–406PubMedCrossRefGoogle Scholar
  15. 15.
    Johansson KA, Appelgren C, Borg KO, Elofsson R (1971) Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93/26 to human serum proteins. Acta Pharm Suec 8: 59PubMedGoogle Scholar
  16. 16.
    Johnsson G, Regardh CG (1976) Clinical pharmacokinetics of β-adrenoreceptor blocking drugs. Clin Pharmacokin 1: 233CrossRefGoogle Scholar
  17. 17.
    Krauss XH, Schalekamp MADH, Kolsters G, Zaal GA, Birkenhäger WH (1972) Effects of betaadrenergic blockade on systemic and renal haemodynamic responses to hyperosmotic saline in hypertensive patients. Clin Sci 43: 385PubMedGoogle Scholar
  18. 18.
    Leren P, Helgeland A, Holme I, Foss PO, Hjermann I, Lund-Larsen PG (1980) Effect of propranolol and prazosin on blood lipids. The Oslo study. Lancet II: 4–7CrossRefGoogle Scholar
  19. 19.
    Lewis PJ (1975) Propranolol — an antihypertensive drug with a central action. In: Davies R (ed) Central action of drugs in blood pressure regulation. University Park Press, Baltimore, pp 206–224Google Scholar
  20. 20.
    Lubbe WF, White DA (1978) Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined α- and β-adrenoreceptor blockade. Clin Sci 55: 283–286Google Scholar
  21. 21.
    Lund-Johanssen P (1979) Hemodynamic consequences of longterm beta-blocker therapy: A 5-year follow-up study of atenolol. J Cardiovasc Pharmacol 1: 487–495CrossRefGoogle Scholar
  22. 22.
    Lydtin H, Kusus T, Daniel W et al. (1972) Propranolol therapy in essential hypertension. Am Heart J 83: 589–595PubMedCrossRefGoogle Scholar
  23. 23.
    Myers MG, Lewis PJ, Reid JL, Dollery CT (1975) Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. J Pharmacol Exp Ther 192: 327–335PubMedGoogle Scholar
  24. 24.
    Niarchos AP, Tarazi RC (1976) Hemodynamic effects of beta-adrenergic blocking agents in hypertension. In: Onestin G, Fernandes MA, Kim KE (eds) Regulation of blood pressure by the central nervous system. Grune & Stratton, New York London, pp 397–409Google Scholar
  25. 25.
    Nies AS, Shand DG (1975) Clinical pharmacology of propranolol. Circulation 52: 6–51PubMedGoogle Scholar
  26. 26.
    Philipp T, Cordes N, Walter B, Walter U, Beyer J, Distler A (1981) Untersuchungen über die Beziehungen zwischen Plasma-noradrenalin, Plasma-renin und blutdrucksenkendem Effekt des β-Rezeptorenblockers ICI 66.082 (Atenolol) bei Patienten mit essentieller HypertonieGoogle Scholar
  27. 27.
    Prichard BNC, Gillam PMS (1969) Treatment of hypertension with propranolol. Br Med J 1: 7–16PubMedCrossRefGoogle Scholar
  28. 28.
    Rahn KH, Gierlichs HW, Planz G, Planz R, Stephany W (1976) The effect of propranolol on plasma catecholamines in hypertensive patients. In: Birkenhäger WH, Vandongen R (eds) Interference with mechanisms in hypertension. ICI Holland B.V., Brüssel, pp 43–46Google Scholar
  29. 29.
    Shand DG (1974) Pharmacokinetic properties of the β-adrenergic receptor blocking drugs. Drugs 7: 39PubMedCrossRefGoogle Scholar
  30. 30.
    Shaw J, England JDF, Hua ASP (1978) Beta blockers and plasma triglycerides. Br Med J 1: 986PubMedCrossRefGoogle Scholar
  31. 31.
    Simpson FO (1974) Beta-adrenergic receptor blocking drugs in hypertension. Drugs 7: 85–105PubMedCrossRefGoogle Scholar
  32. 32.
    Skinner C, Gaddie J, Palmer KNV (1975) Comparison of intravenous AH 5158 (Ibidomide) and propranolol in asthma. Br Med J 2: 59–61PubMedCrossRefGoogle Scholar
  33. 33.
    Stokes GS, Weber MA, Thornell IR (1974) Betablockers and plasma renin activity in hypertension. Br Med J 1: 60–62PubMedCrossRefGoogle Scholar
  34. 34.
    Stumpe KO, Kolloch R, Vetter H, Gramann W, Krück F, Ressel C, Higuchi M (1976) Acute and long-terms studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure. Am J Med 60: 853–865PubMedCrossRefGoogle Scholar
  35. 35.
    Tarazi RC (1973) Long-term hemodynamic effects of betaadrenergic blockade in hypertension. In: Onesti G, Kim KE, Moyer JH (eds) Hypertension: Mechanisms and management. Grune & Stratton, New York London, pp 343–349Google Scholar
  36. 36.
    Tarazi RC, Dustan HP (1972) Beta-adrenergic blockade in hypertension. Am J Cardiol 29: 633–640PubMedCrossRefGoogle Scholar
  37. 37.
    Tjandramaga TB, Thomas J, Verbeeck R, Verbessbelt R, Verbenckmaes R, DeSchepper PJ (1975) The effect on endstage renal failure and hemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol 3: 259Google Scholar
  38. 38.
    Turner P (1979) Relative importance of cardioselectivity and partial agonism in the treatment of hypertension in the patient with air-flow obstruction. Cardiology [Suppl 1] 64: 105–108CrossRefGoogle Scholar
  39. 39.
    Waal-Manning HJ (1976) Hypertension: Which beta-blocker? Drugs 12: 412–441PubMedCrossRefGoogle Scholar
  40. 40.
    Woods JW, Pittman AW, Pulliam CC, Werk EE jr, Waider W, Allen CA (1976) Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone. N Engl J Med 294: 1137–1144PubMedCrossRefGoogle Scholar
  41. 41.
    Zacharias FJ, Cruickshank JM (1979) Treating the elderly hypertensive. Acta Ther 5: 179–190Google Scholar

Literatur

  1. 1.
    Amery A, Bulpitt C, Schaepdryver A de et al. (1978) Glucose intolerance during diuretic therapy. Lancet I: 681CrossRefGoogle Scholar
  2. 2.
    Ames RP, Hill P (1978) Raised serum lipid concentrations during diuretic treatment of hypertension: A study of predictive indexes. Clin Sci 55: 311Google Scholar
  3. 3.
    Berglund G, Andersson O (1981) Beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects. Lancet I 744CrossRefGoogle Scholar
  4. 4.
    Bühler FR, Burkart F, Lütold BE, Kung M, Marbet G, Pfisterer M (1975) Antihypertensive beta blocking action as related to renin and age: A pharmacological tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 36: 653PubMedCrossRefGoogle Scholar
  5. 5.
    Bulpitt CJ (1975) Serum uric acid in hypertensive patients. Br Heart J 12: 1210CrossRefGoogle Scholar
  6. 6.
    Cannon PJ, Stason WB, Dermartini FE, Sommers SC, Laragh JH, (1966) Hyperuricaemia in primary and renal hypertension. N Engl J Med 275: 457PubMedCrossRefGoogle Scholar
  7. 7.
    England JDF, Simons LA, Gibson JC, Carlton M (1980) The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clin Exp Pharmacol Physiol 7: 329PubMedCrossRefGoogle Scholar
  8. 8.
    Goldman A, Steele B, Schnaper H, Fitz A, Frohlich E, Perry HM (1980) Serum lipoprotein levels during chlorthalidone therapy. JAMA 244: 1691PubMedCrossRefGoogle Scholar
  9. 9.
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 62: 707PubMedCrossRefGoogle Scholar
  10. 10.
    Grimm RH, Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H (1981) Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med 94: 7PubMedGoogle Scholar
  11. 11.
    Healy JJ, McKenna TJ, Canning B, Brienst J, Duffy GJ, Muldowney FP (1970) Body composition changes in hypertensive subjects on long-term oral diuretic therapy. Br Med J 1: 716PubMedCrossRefGoogle Scholar
  12. 12.
    Helgeland A (1980) Treatment of mild hypertension: A five year controlled drug trial. The Oslo study. Am J Med 69: 725PubMedCrossRefGoogle Scholar
  13. 13.
    Helgeland A, Hjermann I, Leren P (1978) High-density lipoprotein cholesterol and antihypertensive drugs: The Oslo study. Br Med J 2: 403PubMedCrossRefGoogle Scholar
  14. 14.
    Helgeland A, Hjermann I, Leren P, Enger S, Holme I (1978) High-density lipoprotein cholesterol and antihypertensive drugs. The Oslo study. Br Med J 2: 403PubMedCrossRefGoogle Scholar
  15. 15.
    Hypertension Detection and Follow-up Program Cooperative Group (1979) Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242: 2562CrossRefGoogle Scholar
  16. 16.
    Jarrett RJ, Keen H, Fuller JH, McCartney M (1977) Treatment of borderline diabetes: controlled trial using carbohydrate restriction and phenformin. Br Med J 2: 861PubMedCrossRefGoogle Scholar
  17. 17.
    Leren P (1981) Antihypertensive drugs and blood lipids: The Oslo study. Symposium on CHD risk factors and antihypertensive drug selection. 54th Scientific Sessions of the American Heart Association, November 19, 1981, Dallas, Texas, USAGoogle Scholar
  18. 18.
    Leren P, Helgeland A, Holme I, Foss PO, Hjermann I, Lund-Larsen PG (1980) Effect of propranolol and prazosin on blood lipids. The Oslo study. Lancet II 4CrossRefGoogle Scholar
  19. 19.
    Lund-Johansen P (1979) Hemodynamic consequences of long-term beta-blocker therapy: A 5-year follow-up study of atenolol. J Cardiovasc Pharmacol 1: 487PubMedCrossRefGoogle Scholar
  20. 20.
    Newland H (1975) Hyperuricaemia in coronary, cerebral and peripheral arterial disease: an explanation. Med Hypotheses I: 152CrossRefGoogle Scholar
  21. 21.
    Peart WS, Cochrane AL, Dollery CT et al. (1977) Randomised controlled trial of treatment for mild hypertension: Design and pilot trial. Br Med J 1: 1437CrossRefGoogle Scholar
  22. 22.
    Report by the Management Commitee (1980)The Australian therapeutic trial in mild hypertension. Lancet I: 1261Google Scholar
  23. 23.
    Report of Medical Research Council Working Party on Mild to Moderate Hypertension (1981) Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet II: 539Google Scholar
  24. 24.
    Schnaper H, Fitz A, Frohlich E, Goldman A, Perry HM jr, Steele B (1977) Chlorthalidone and serum cholesterol. Lancet II: 295CrossRefGoogle Scholar
  25. 25.
    Shaw J, England JDF, Hua ASP (1978) Beta blockers and plasma triglycerides. Br Med J 1: 986PubMedCrossRefGoogle Scholar
  26. 26.
    Stumpe KO, Overlack A (1979) Diuretics, β-blockers or both as treatment for essential hypertension. Br J Clin Pharmacol 7: 189SPubMedGoogle Scholar
  27. 27.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents (1970) Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 213: 1143CrossRefGoogle Scholar
  28. 28.
    Wright AD, Barber SG, Kendall MJ, Poole PH (1979) Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus. Br Med J 1: 159PubMedCrossRefGoogle Scholar
  29. 29.
    Zacharias FJ, Cruickshank JM (1979) Treating the elderly hypertensive. Acta Therapeutica 5: 179Google Scholar

Literatur: Einleitung

  1. 1.
    Ablod B (1963) A study of the hemodynamic effects of hydralazine in man. Acta Pharmacol Toxicol (Copenh) [Suppl I] 20: 1Google Scholar
  2. 2.
    Gottlieb TT, Katz FH, Chidsey CA III (1972) Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension: a comparative study of minoxidil and hydralazine. Circulation 45: 571PubMedGoogle Scholar
  3. 3.
    Hansson L, Olander R, Aberg H et al. (1971) Treatment of hypertension with propranolol and hydralazine. Acta Med Scand 190: 521Google Scholar
  4. 4.
    Koch-Weser J (1974) Vasodilator drugs in the treatment of hypertension. Arch Intern Med 133: 1017PubMedCrossRefGoogle Scholar
  5. 5.
    Koch-Weser J (1975) The vasodilator antihypertensives. Drug Ther Bull 5/5: 67Google Scholar
  6. 6.
    Kuchel O, Fishman LM, Liddle G et al. (1967) Effect of diazoxide on plasma renin activity in hypertensive patients. Ann Intern Med 67: 191Google Scholar
  7. 7.
    Zacest R, Gilmore E, Koch-Weser J (1972) Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med 286: 617PubMedCrossRefGoogle Scholar

Literatur: Dihydralazin

  1. 1.
    Ablad B (1963) A study of the mechanism of the hemodynamic effects of hydralazine in man. Acta Pharmacol Toxicol (Copenh) 20: 1Google Scholar
  2. 2.
    Aenishänslin W, Pestalozzi-Kerpel J, Dubach UC et al. (1972) Antihypertensive therapy with adrenergic beta-receptor blockers and vasodilators. Eur J Clin Pharmacol 4: 177PubMedCrossRefGoogle Scholar
  3. 3.
    Alarcon-Segovia D, Wakin KG, Worthington JW, Wand LE (1967) Clinical and experimental studies on the hydralazine syndrome arid its relationship to systemic lupus erythematosus. Medicine 46: 1PubMedCrossRefGoogle Scholar
  4. 4.
    Baum T, Shrophshire AT, Varner LL (1972) Contribution of the CNS to the action of several antihypertensive agents (methyldopa, hydralazine, guanethidine). J Pharmacol Exp Ther 182: 135PubMedGoogle Scholar
  5. 5.
    Chatterjee K, Massie B, Rubin S, Gelberg H, Brundage BH, Ports TA (1978) Long-term outpatient vasodilator therapy of congestive heart failure. Am J Med 65: 134PubMedCrossRefGoogle Scholar
  6. 6.
    Finnerty FA Jr (1971) Relationship of extracellular fluid volume to the development of drug resistance in the hypertensive patient. Am Heart J 81: 563PubMedCrossRefGoogle Scholar
  7. 7.
    Finnerty FA Jr (1975) Hypertension in pregnancy. Clin Obstet Gynecol 18: 145PubMedCrossRefGoogle Scholar
  8. 8.
    Fitchett DH, Marin JA, Oakley CM, Goodwin JF (1979) Hydralazine in the management of left ventricular failure. Am J Cardiol 40: 303CrossRefGoogle Scholar
  9. 9.
    Franciosa J, Pierpont B, Cohn J (1970) Hemodynamic improvement after oral hydralazine in left ventricular failure; a comparison with nitroprusside infusion in 16 patients. Ann Intern Med 86: 388Google Scholar
  10. 10.
    Freis ED, Rose JC, Higgins TF et al. (1953) The hemodynamic effects of hypotensive drugs in man. IV. l-hydrazinophthalazine. Circulation 8: 199PubMedGoogle Scholar
  11. 11.
    Gilmore E, Weil J, Chidsey C (1970) Treatment of essential hypertension with a new vasodilator in combination with B-adrenergic blockade. N Engl J Med 282: 521PubMedCrossRefGoogle Scholar
  12. 12.
    Glazer N (1972) Reserpine, hydralazine, hydrochlorothiazide combination (Serapes) in essential hypertension. Nebr Symp Motiv 14: 561Google Scholar
  13. 13.
    Goodman LS, Gilman A (eds) (1975) The Pharmacological basis of therapeutics, 5th edn. MacMillan, New York, p 705Google Scholar
  14. 14.
    Gottlieb TB, Katz FH, Chidsey CA III (1972) Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension: A comparative study of minoxidil and hydralazine. Circulation 45: 571PubMedGoogle Scholar
  15. 15.
    Ingenito A, Barrett J, Procita L (1969) Centrally mediated peripheral hypotensive effects of reserpine and hydralazine when perfused through the isolated in situ cat brain. J Pharmacol Exp Ther 170: 210PubMedGoogle Scholar
  16. 16.
    Isaac LSM, Kanda M (1964) The metabolism of l-hydrazinoph-thalazine. Pharmacology 143: 7Google Scholar
  17. 17.
    Koch-Weser J (1974) Hypertensive emergencies. N Engl J Med 290: 211PubMedCrossRefGoogle Scholar
  18. 18.
    Koch-Weser J (1974) Vasodilator drugs in the treatment of hypertension. Arch Intern Med 133: 1017PubMedCrossRefGoogle Scholar
  19. 19.
    Koch-Weser J (1976) Drug therapy: Hydralazine. N Engl J Med 295: 320PubMedCrossRefGoogle Scholar
  20. 20.
    Lee SL, Chase PH (1975) Drug-induced systemic lupus erythematosus: A critical review. Semin Arthritis Rheum 5: 83PubMedCrossRefGoogle Scholar
  21. 21.
    Lesser JM, Israili ZH, Davis DC et al. (1974) Metabolism and disposition of hydralazine- C in man and dog. Drug Metab Dispos 2: 351PubMedGoogle Scholar
  22. 22.
    McMahon G (1978) Management of essential hypertension. Futura, New YorkGoogle Scholar
  23. 23.
    McNicol MW, Hutchinson HE (1956) Severe toxic reaction to hydralazine. Lancet II: 1288CrossRefGoogle Scholar
  24. 24.
    Moore JD, Perry HN Jr (1966) Radioautographic localization of hydralazine-l-C14 in arterial walls. Proc Soc Exp Biol Med 122: 576Google Scholar
  25. 25.
    Morrow JD, Schroeder HA, Perry HM Jr (1953) Studies in the control of hypertension by hyphex. II. Toxic reactions and side effects. Circulation 8: 829PubMedGoogle Scholar
  26. 26.
    Moyer JH, Head-Hadley CA (1950) Renal function and systemic blood pressure changes following the administration of hydrazinophthalazine. J Lab Clin Med 36: 969PubMedGoogle Scholar
  27. 27.
    Moyer J, Handley C, Huggins R (1951) Some pharmacodynamic effects of l-hydrazinzinophthalazine with particular reference to renal function and cardiovascular response. J Pharmacol 103: 368Google Scholar
  28. 28.
    O’Malley K, Segal J, Israili Z et al. (1975) Duration of hydralazine action in hypertension. Clin Pharmacol Ther 18: 581PubMedGoogle Scholar
  29. 29.
    Pape J (1974) The effect of alprenalol in combination with hydralazine in essential hypertension. A double-blind, crossover study and a long-term follow-up study. Acta Med Scand 554: 55Google Scholar
  30. 30.
    Perry HM Jr (1973) Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 54: 58PubMedCrossRefGoogle Scholar
  31. 31.
    Perry HM Jr, Tan EM, Carmody S, Sakanata A (1970) Relationship of actyl transference activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 76: 114PubMedGoogle Scholar
  32. 32.
    Persson I (1975) Combination therapy of essential hypertension with pindolol (Visken) and hydralazine. Eur J Clin Pharmacol 9: 91PubMedCrossRefGoogle Scholar
  33. 33.
    Pettinger WA, Keeton K (1959) Altered renin release and propranolol potentiation of vasodilatory drug hypotension. Clin Invest 55: 236Google Scholar
  34. 34.
    Raskin NH, Fishman RA (1965) Pyridoxine-deficiency neuropathy due to hydralazine. N Engl J Med 783: 1182CrossRefGoogle Scholar
  35. 35.
    Reidenberg MM, Drayer D, DeMarco A et al. (1973) Hydralazine elimination in man. Clin Pharmacol Ther 14: 970PubMedGoogle Scholar
  36. 36.
    Rogers S, Flowers C, Alexander A (1969) Aggressive toxemia management. Obstet Gynecol 33: 724PubMedCrossRefGoogle Scholar
  37. 37.
    Sannerstedt R, Stenberg J, Vedin A et al. (1972) Chronic beta adrenergic blockade in arterial hypertension: Hemodynamic influences of dihydralazine and dynamic exercise and clinical effects of combined treatment. Am J Cardiol 29: 718PubMedCrossRefGoogle Scholar
  38. 38.
    Siitonen L, Jänne J, Keyriläinen O et al. (1974) Hydralazine and beta-adrenergic blockade in the treatment of hypertension. Ann Clin Res 6: 341PubMedGoogle Scholar
  39. 39.
    Slonium NB (1954) Arthralgia, headache, prostration and fever during hydralazine therapy. JAMA 154: 1419Google Scholar
  40. 40.
    Stunkard A, Wertheimer L, Redisch W (1954) Studies on hydralazine: evidence for a peripheral site of action. J Clin Invest 33: 1047PubMedCrossRefGoogle Scholar
  41. 41.
    Talseth T (1976) Studies on hydralazine. III. Bioavailability of hydralazine in man. Eur J Clin Pharmacol 10: 395PubMedCrossRefGoogle Scholar
  42. 42.
    Talseth T (1976) Studies on hydralazine. 1. Serum concentrations of hydralazine in man after a single dose and at steady-state. Eur J Clin Pharmacol 10: 183CrossRefGoogle Scholar
  43. 43.
    Ueda H, Kaneko Y, Takeda T et al. (1970) Observations on the mechanism of renin release by hydralazine in hypertensive patients. Circ Res 27: 201PubMedGoogle Scholar
  44. 44.
    Zacest R, Koch-Weser J (1972) Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther 13: 420PubMedGoogle Scholar
  45. 45.
    Zacest R, Gilmore E, Koch-Weser J (1972) Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med 286: 617PubMedCrossRefGoogle Scholar

Literatur: Minoxidil

  1. 1.
    Alpert MA, Bauer JH, Parker BM, Brooks CS, Freeman JA (1979) Pulmonary hemodynamics in systemic hypertension: long-term effect of minoxidil. Chest 76: 379PubMedCrossRefGoogle Scholar
  2. 2.
    Atkins JM, Mitchell HC, Pettinger WA (1977) Increased pulmonary vascular resistance with systemic hypertension effect of minoxidil and other antihypertensive agents. Am J Cardiol 39: 802PubMedCrossRefGoogle Scholar
  3. 3.
    Bauer JH, Alpert MA (1980) Rapid reduction of severe hypertension with minoxidil. J Cardiovasc Pharmacol [Suppl] 2: 189CrossRefGoogle Scholar
  4. 4.
    Brunner HR, Jaeger P, Ferguson RK, Jequier E, Turini G, Gavras H (1978) Need for beta-blok-kade in hypertension reduced with long-term minoxidil. Br Med J II: 385CrossRefGoogle Scholar
  5. 5.
    Campese V, Stein D, DeQuattro V (1979) Treatment of severe hypertension with minoxidil: Avantages and limitations, J Clin Pharmacol 19: 231PubMedGoogle Scholar
  6. 6.
    Dormois JC, Young HL, Nies AS (1975) Minoxidil in severe hypertension: value when conventional drugs have failed. Am Heart J 90: 360PubMedCrossRefGoogle Scholar
  7. 7.
    DuCharme DW, Freyburger WA, Graham BE, Carlson RG (1973) Pharmacologic properties of minoxidil: a new hypotensive agent. J Pharmacol Exp Ther 184: 662PubMedGoogle Scholar
  8. 8.
    Gilmore E, Weil J, Chidsey C (1970) Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade. N Engl J Med 282: 571CrossRefGoogle Scholar
  9. 9.
    Gottlieb TB, Thomas RC, Chidsey CA (1972) Pharmacokinetic studies of minoxidil. Clin Pharmacol Ther 13: 436PubMedGoogle Scholar
  10. 10.
    Grim CE, Luft FC, Grim CM, Klotman PE, Van Huysse JW, Weinberger WH (1979) Rapid blood pressure control with minoxidil: acute and chronic effects on blood pressure, sodium excretion and the renin-aldosterone system. Arch Intern Med 139: 529PubMedCrossRefGoogle Scholar
  11. 11.
    Hall D, Froer KL, Rudolph W (1980) Serial electrocardiographic changes during long-term treatment of severe hypertension with minoxidil. J Cardiovasc Pharmacol [Suppl] 2: 200CrossRefGoogle Scholar
  12. 12.
    Hermann BH, Balazs I, Young R, Earl FL, Krop S, Ferrans VJ (1979) Acute cardiomyopathy induced by the vasodilating antihypertensive agent minoxidil. Toxicol Appl Pharmacol 47: 493CrossRefGoogle Scholar
  13. 13.
    Kern T, DeQuattro V, Bornheimer J, DeQuattro E, Kolloch R (1980) Long-term effects of minoxidil therapy on renal function of patients with refractory hypertension: significance of albuminuria. J Cardiovasc Pharmacol [Suppl 2] 2: 156CrossRefGoogle Scholar
  14. 14.
    Keusch G, Weidmann P, Campese V et al. (1978) Minoxidil therapy in refractory hypertension analysis of 155 patients. Nephron 21: 1PubMedCrossRefGoogle Scholar
  15. 15.
    Klotman PE, Grim CE, Weinberg MH, Hudson WE (1977) The effects of minoxidil on pulmonary and systemic hemodynamics in hypertensive man. Circulation 55: 394PubMedGoogle Scholar
  16. 16.
    Limas CJ, Freis ED (1973) Minoxidil in severe hypertension with renal failure. Am J Cardiol 31: 355PubMedCrossRefGoogle Scholar
  17. 17.
    Lowenthal DT, Affrime MB (1980) Pharmacology and pharmacokinetics of minoxidil. J Cardiovasc Pharmacol [Suppl] 2: 93CrossRefGoogle Scholar
  18. 18.
    Martin WB, Spodick DH, Zins GR (1980) Pericardial disorders occurring during open-label study of 1869 severely hypertensive patients treated with minoxidil. J Cardiovasc Pharmacol [Suppl] 2: 217CrossRefGoogle Scholar
  19. 19.
    Mitchell HC, Pettinger WA (1978) Long-term treatment of refractory hypertensive patients with monoxidil. JAMA 239: 2131PubMedCrossRefGoogle Scholar
  20. 20.
    Mitchell HC, Pettinger WA (1980) Renal function in long term minoxidiltreated patients. J Cardiovasc Pharmacol [Suppl] 2: 163CrossRefGoogle Scholar
  21. 21.
    Mitchell HC, Pettinger WA (1980) The hypernoradrenergic state in vasodilator drug-treated hypertensive patients: effect of clonidine. J Cardiovasc Pharmacol 2: 1PubMedCrossRefGoogle Scholar
  22. 22.
    Mutterperl RE, Diamond FB, Lowenthal DT (1976) Long-term effects of minoxidil in the treatment of malignant hypertension in chronic renal failure. J Clin Pharmacol 16: 498PubMedGoogle Scholar
  23. 23.
    O’Malley K, Velasco M, Wells J, McNay JL (1975) Control plasma renin activity and changes in sympathetic tone as determinants of minoxidilinduced increase in plasma renin activity. J Clin Invest 55: 230PubMedCrossRefGoogle Scholar
  24. 24.
    Pettinger WA, Mitchell HC (1971) Minoxidil — an alternative to nephrectomy for refractory hypertension. N Engl J Med 289: 167CrossRefGoogle Scholar
  25. 25.
    Pettinger WA, Mitchell HC (1975) Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man. N Engl J Med 292: 1214PubMedCrossRefGoogle Scholar
  26. 26.
    Pluss RG, Orcutt J, Chidsey CA (1972) Tissue distribution and hypotensive effects of minoxidil in normotensive rats. J Lab Clin Med 79: 47Google Scholar
  27. 27.
    Sannerstedt R, Brorson L, Berglund G, Werkô L (1975) Minoxidil — haemodynamic and clinical experiences with a new peripheral vasodilator. Acta Med Scand 197: 409PubMedCrossRefGoogle Scholar
  28. 28.
    Sinaiko AR, O’Dea RF, Mirkin BL (1980) Clinical response of hypertensive children to long-term minoxidil therapy. J Cardiovasc Pharmacol [Suppl] 2: 181CrossRefGoogle Scholar
  29. 29.
    Tarazi RC, Magrini F, Dustan HP, Bravo EL, Garvey J (1975) Pulmonary hypertension with diazoxide and minoxidil. Am J Cardiol 35: 172CrossRefGoogle Scholar
  30. 30.
    Thomas RC, Hsi RSP, Harpootlian H, Judy RW (1975) Metabolism of minoxidil, a new hypotensive agent. I. Absorption, distribution and excretion following administration to rats, dogs and monkeys. J Pharm Sci 64: 1360PubMedCrossRefGoogle Scholar
  31. 31.
    Velasco M, O’Malley K, Robic NW, Wells J, Israili ZH, McNay JL (1974) Differential effects of propranolol on heart rate and plasma renin activity in patients treated with minoxidil. Clin Pharmacol Ther 16: 1031PubMedGoogle Scholar
  32. 32.
    Watkins J, Dargie HJ, Bune A, Dollery CT (1979) Reduction of betablocking drugs in hypertensive patients treated with minoxidil. Br Med J I: 1400CrossRefGoogle Scholar
  33. 33.
    Weidmann P, Keusch G (1977) Behandlung des therapieresistenten Hochdrucks. Schweiz Med Wochenschr 107: 1081PubMedGoogle Scholar
  34. 34.
    Wilburn RL, Blaufuss A, Bennett CM (1975) Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide. Circulation 52: 706PubMedGoogle Scholar
  35. 35.
    Zacest R, Gilmore E, Koch-Weser J (1972) Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med 286: 617PubMedCrossRefGoogle Scholar
  36. 36.
    Zacest R, Frewin DB, Robinson MA, Wilson LL, Lawrence JR, Clarkson AR, Jackson B (1976) Clinical and haemodynamic effects of minoxidil in refractory hypertension. Drugs [Suppl 1] 11: 177Google Scholar

Literatur: Diazoxid

  1. 1.
    Baer L, Goodwin FJ, Laragh JH (1969) Diazoxide-induced renin release in man: dissocation from plasma and extracellular fluid volume changes. J Clin Endocrinol Metab 29: 1107PubMedCrossRefGoogle Scholar
  2. 2.
    Bartorelli C, Gargano N, Leonetti G et al. (1963) Hypotensive and renal effects of diazoxide, a sodium-retaining benzothiadiazine compound. Circulation 27: 895PubMedGoogle Scholar
  3. 3.
    Bhatia SK, Fröhlich ED (1973) Hemodynamic comparison of agents useful in hypertensive emergencies. Am Heart J 85: 367CrossRefGoogle Scholar
  4. 4.
    Charles MA, Danforth E Jr (1971) Nonketoacidotic hyperglycemia and coma during intravenous diazoxide therapy in uremia. Diabetes 20: 501PubMedGoogle Scholar
  5. 5.
    Finnerty FA (1972) Hypertensive encephalopathy. Am J Med 52: 672PubMedCrossRefGoogle Scholar
  6. 6.
    Finnerty FA Jr, Kakaviatos N, Tuckman J et al. (1963) Clinical evaluation of diazoxide: a new treatment for acute hypertension. Circulation 28: 203PubMedGoogle Scholar
  7. 7.
    Hamby WM, Jankowski GJ, Pouget JM et al. (1968) Intravenous use of diazoxide in the treatment of severe hypertension. Circulation 37: 169Google Scholar
  8. 8.
    Hutcheon DE, Barthalmus KS (1962) Antihypertensive action of diazoxide: a new benzothiadiazine with antidiuretic properties. Br Med J II: 159CrossRefGoogle Scholar
  9. 9.
    Johnson BF (1971) Diazoxide and renal function in man. Clin Pharmacol Ther 12: 815PubMedGoogle Scholar
  10. 10.
    Kanada SA, Kanada DJ, Hutchinson RA, Wu D (1976) Angina-like syndrome with diazoxide therapy for hypertensive crisis. Ann Intern Med 84/6: 696Google Scholar
  11. 11.
    Koch-Weser J (1973) Vasodilatation for vasospastic hypertension. N Engl J Med 189: 213CrossRefGoogle Scholar
  12. 12.
    Koch-Weser J (1974) Vasodilator drugs in the treatment of hypertension. Arch Intern Med 133: 1017PubMedCrossRefGoogle Scholar
  13. 13.
    Koch-Weser J (1974) Hypertensive emergencies. N Engl J Med 290: 211PubMedCrossRefGoogle Scholar
  14. 14.
    Koch-Weser J (1976) Drug therapy: Diazoxide. N Engl J Med 294: 1271PubMedCrossRefGoogle Scholar
  15. 15.
    Koch-Weser J, Sellers EM (1971) Drug interactions with coumarin anticoagulants. N Engl J Med 185: 487CrossRefGoogle Scholar
  16. 16.
    Küchel O, Fishman LM, Liddle GW et al. (1967) Effect of diazoxide on plasma renin activity in hypertensive patients. Ann Intern Med 57: 791Google Scholar
  17. 17.
    Lockwood CH, Nicholis DM, Troop VL et al. (1963) Diazoxide therapy in hypertension. Am J Med Sci 246: 312PubMedCrossRefGoogle Scholar
  18. 18.
    Michael CA (1972) Diazoxide in acute obstetrical emergencies. Aust NZ J Obstet Gynaecol 12: 48CrossRefGoogle Scholar
  19. 19.
    Miller WE, Gifford RW Jr, Humphrey DC et al. (1969) Management of severe hypertension with intravenous injections of diazoxide. Am J Cardiol 24: 870PubMedCrossRefGoogle Scholar
  20. 20.
    Moser M (1974) Diazoxide — an effective vasodilator in accelerated hypertension. Am Heart J 87/6: 791CrossRefGoogle Scholar
  21. 21.
    Mroczek WJ, Leibel BA, Davidov M et al. (1971) The importance of the rapid administration of diazoxide in accelerated hypertension. N Engl J Med 285: 603PubMedCrossRefGoogle Scholar
  22. 22.
    Nayler WG, McInnes I, Swann JB et al. (1968) Some effects of the hypotensive drug diazoxide on the cardiovascular system. Am Heart J 75: 223PubMedCrossRefGoogle Scholar
  23. 23.
    O’Malley K, Velasco M, Pruitt A et al. (1975) Decreased plasma protein binding of diazoxide in uremia. Clin Pharmacol Ther 18: 53PubMedGoogle Scholar
  24. 24.
    Pohl JEF, Thurston H (1971) Use of diazoxide in hypertension with renal failure. Br Med J IV: 142CrossRefGoogle Scholar
  25. 25.
    Powell WJ Jr, Green RM, Whiting RB et al. (1971) Action of diazoxide on skeletal muscle vascular resistance. Circ Res 28: 167PubMedGoogle Scholar
  26. 26.
    Pruitt AW, Faraj BA, Dayton PG (1974) Metabolism of diazoxide in man and experimental animals. J Pharmacol Exp Ther 188: 248PubMedGoogle Scholar
  27. 27.
    Rubin AA, Roth FE, Tylor RM et al. (1962) Pharmacology of diazoxide, an antihypertensive, nondiuretic benzothiadiazine. J Pharmacol Exp Ther 136: 344PubMedGoogle Scholar
  28. 28.
    Rubin AA, Zitowitz L, Hausier I (1963) Acute circulatory effects of diazoxide and sodium nitrite. J Pharmacol Exp Ther 140: 46PubMedGoogle Scholar
  29. 29.
    Sellers EM, Koch-Weser J (1969) Protein binding and vascular activity of diazoxide. N Engl J Med 281: 1141PubMedCrossRefGoogle Scholar
  30. 30.
    Sellers EM, Koch-Weser J (1973) Influence of intravenous injection rate on protein binding and vascular activity of diazoxide. Ann NY Acad Sci 226: 319PubMedCrossRefGoogle Scholar
  31. 31.
    Sellers EM, Koch-Weser J (1974) Binding of diazoxide and other benzothiadiazines to human albumin. Biochem Pharmacol 23: 553PubMedCrossRefGoogle Scholar
  32. 32.
    Symchowicz S, Winston L, Black J et al. (1967) Diazoxide blood levels in man. J Pharm Sci 56: 912PubMedCrossRefGoogle Scholar
  33. 33.
    Taylor RM, Rubin AA (1964) Studies on the renal pharmacology of diazoxide, an antidiuretic benzothiadiazine. J Pharmacol Exp Ther 144: 284PubMedGoogle Scholar
  34. 34.
    Thirwell MP, Zsotér TT (1972) The effect of diazoxide on the veins. Am Heart J 83: 512PubMedCrossRefGoogle Scholar
  35. 35.
    Thomson AE, Nickerson M, Gaskell P et al. (1962) Clinical observations on an antihypertensive chlorothiazide analogue devoid of diuretic activity. Can Med Assoc J 87: 1306PubMedGoogle Scholar
  36. 36.
    Updike SJ, Harrington AR (1969) Acute diabetic ketoacidosis: a complication of intravenous diazoxide treatment for refractory hypertension. N Engl J Med 280: 768PubMedCrossRefGoogle Scholar
  37. 37.
    Wilson WR, Okun R (1963) The acute hemodynamic effects of diazoxide in man. Circulation 28: 89PubMedGoogle Scholar

Literatur: Nitroprussid-Natrium

  1. 1.
    Adams AP, Clarke TNS, Edmonds-Seal J et al. (1973) Effects of sodium nitroprusside on myocardial contractility and haemodynamics. Br J Anaesth 45: 120PubMedGoogle Scholar
  2. 2.
    Ahearn DJ, Grim CE (1974) Treatment of malignant hypertension with sodium nitroprusside. Arch Intern Med 133: 187PubMedCrossRefGoogle Scholar
  3. 3.
    Bastron RD, Kaloyanides GJ (1972) Effect of sodium nitroprusside on function in the isolated intact dog kidney. J Pharmacol Exp Ther 181: 244PubMedGoogle Scholar
  4. 4.
    Bhatia SK, Frohlich ED (1973) Hemodynamic comparison of agents useful in hypertensive emergencies. Am Heart J 85: 367CrossRefGoogle Scholar
  5. 5.
    Chatterjee K, Parmley WW, Ganz W et al. (1973) Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction. Circulation 48: 1183PubMedGoogle Scholar
  6. 6.
    Cohen IM, Mottet MM et al. (1976) Danger in nitroprusside therapy. Ann Intern Med 85/2: 205Google Scholar
  7. 7.
    Cromme F (1891) Beitrag zur Kenntnis der Wirkung des Nitroprussid-Natrium. Dissertation, Universität KielGoogle Scholar
  8. 8.
    Editorial (1975) Sodium nitroprusside in anaesthesia. Br Med J III: 38Google Scholar
  9. 9.
    Franciosa JA, Guiha NH, Limas CJ et al. (1972) Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet I: 650CrossRefGoogle Scholar
  10. 10.
    Gifford RW Jr (1962) The treatment of hypertensive emergencies. Am J Cardiol 9: 880PubMedCrossRefGoogle Scholar
  11. 11.
    Gmeiner R, Reidt J, Baumgartner H (1975) Effect of sodium nitroprusside on myocardial performance and venous tone. Eur J Pharmacol 31: 287PubMedCrossRefGoogle Scholar
  12. 12.
    Goodman LS, Gilman A (1975) The pharmacological basis of therapeutics, 5th edn. MacMillan, New York, p 715Google Scholar
  13. 13.
    Guiha NH, Cohn JN, Mikulic E et al. (1974) Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 291: 587PubMedCrossRefGoogle Scholar
  14. 14.
    Höbel M, Kreye VAW, Raithelhuber A (1976) Natrium-Nitroprussid: Toxizität, Stoffwechsel und Organverteilung. Herz 1: 130Google Scholar
  15. 15.
    Jack RD (1974) Toxicity of sodium nitroprusside. Br J Anaesth 46: 952PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson CC (1929) The actions and toxicity of sodium nitroprusside. Arch Int Pharmacodyn Ther 35: 480Google Scholar
  17. 17.
    Koch-Weser J (1974) Hypertensive emergencies. N Engl J Med 290: 211PubMedCrossRefGoogle Scholar
  18. 18.
    Page IH, Corcoran AC, Dustan HP et al. (1955) Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation 11: 188PubMedGoogle Scholar
  19. 19.
    Palmer RF, Lasseter KC (1975) Sodium nitroprusside. N Engl J Med 292: 294PubMedCrossRefGoogle Scholar
  20. 20.
    Palmer RF, Seelman RC, Wheat MW (1965) Pharmacological approach to the therapy of acute dissecting aneurysm of the aorta. Clin Res 13: 27Google Scholar
  21. 21.
    Rowe GG, Henderson RH (1974) Systemic and coronary hemodynamic effects of sodium nitroprusside. Am Heart J 87: 83PubMedCrossRefGoogle Scholar
  22. 22.
    Schiffmann H, Fuchs P (1966) Controlled hypotension effected by sodium nitroprusside. Acta Anaesthesiol Scand 23: 704CrossRefGoogle Scholar
  23. 23.
    Schlant RC, Tsagaris TS, Robertson RJ Jr (1962) Studies on the acute cardiovascular effects of intravenous sodium nitroprusside. Am J Cardiol 9: 51PubMedCrossRefGoogle Scholar
  24. 24.
    Styles M, Coleman AJ, Leary WP (1973) Some hemodynamic effects of sodium nitroprusside. Anesthesiology 38: 173PubMedCrossRefGoogle Scholar
  25. 25.
    Tinker JH, Michenfelder JD (1976) Sodium nitroprusside: Pharmacology, toxicology and therapeutics. Anesthesiology 45: 340PubMedCrossRefGoogle Scholar
  26. 26.
    Wilbrandt R, Piehl W, Neuhaus G et al. (1970) Die Behandlung hypertoner Krisen mit Natriumprussid. Dtsch Med Wochenschr 36: 1822CrossRefGoogle Scholar

Literatur: Kalziumantagonisten

  1. 1.
    Akihama T, Mamiya S, Miura A, Yamaguchi M (1978) Clinical effect of diltiazem hydrochloride in hypertension. Mod Clin Med 20: 1507Google Scholar
  2. 2.
    Aoki K, Yosida T, Katos K, Tazumi K, Sato I, Takikawa K, Hoffa K (1976) Hypotensive action and increased plasma renin activity by a Ca2+ (nifedipine) in hypertensive patients. Jpn Heart J 17: 479PubMedCrossRefGoogle Scholar
  3. 3.
    Atterhöf JH, Ekelund LG (1975) Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men. Eur J Clin Pharmacol 8: 317CrossRefGoogle Scholar
  4. 4.
    Bachour G, Bender F, Wessels F, Losse H (1976) Orale Hypertoniebehandlung mit dem Calciumantagonisten Verapamil. Verh Dtsch Ges Inn Med 82: 1334PubMedGoogle Scholar
  5. 5.
    Beer N, Gallegos I, Cohen A, Klein N, Sonnenblick E, Frishman W (1981) Efficiacy of sublingual nifedipine in the acute treatment of systemic hypertension. Chest 79: 571PubMedCrossRefGoogle Scholar
  6. 6.
    Brittinger WD, Strauch M, Huber W, Koch WD, Henning GE, Wittenmeier KW, Twittenhoff WD (1969) Iproveratril als Antihypertonikum bei krisenhafter renaler Hypertonie. Dtsch Med Wochenschr 94: 945PubMedCrossRefGoogle Scholar
  7. 7.
    Brittinger WD, Schwarzbeck A, Wittenmeier KW et al. (1970) Klinisch-experimentelle Untersuchungen über die blutdrucksenkende Wirkung von Verapamil. Dtsch Med Wochenschr 95: 1871PubMedCrossRefGoogle Scholar
  8. 8.
    Bühler FR, Hulthen L (1982) Calcium channel blockers: a pathophysiologically based antihypertensive treatment concept for the future? Eur J Clin Invest 12: 1PubMedCrossRefGoogle Scholar
  9. 9.
    Bühler FR, Hulthén U, Kiowski W, Bolli P (1982) Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients. Clin Sci 63: 439Google Scholar
  10. 10.
    De Leeuw PW, Smout AJPM, Willemse PJ, Birkenhäger WK (1981) Effects of verapamil in hypertensive patients. In: Zanchetti A, Krikler DM (eds) Calcium anatagonism in cardiovascular therapy. Excerpta Medica, Amsterdam Oxford Princeton, p 233Google Scholar
  11. 11.
    Doyle AE, Anavekar SN, Oliver LE (1981) A clinical trial of verapamil in the treatment of hypertension. In: Zanchetti A, Krikler DM (eds) Calcium antagonism in cardiovascular therapy. Excerpta Medica, Amsterdam Oxford Princeton, p 252Google Scholar
  12. 12.
    Ebner F (1977) Wirkung und Verträglichkeit von Adalat bei Kombination mit verschiedenen Medikamenten. Münch Med Wochenschr [Suppl 1] 199: 1Google Scholar
  13. 13.
    Eichelbaum M, Somogyi A (1981) Verapamil distribution in health and the diseased state. In: Zanchetti A, Krikler DM (eds) Calzium antagonism in cardiovascular therapy. Excerpta Medica, Amsterdam Oxford Princeton, p 64Google Scholar
  14. 14.
    Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Annu Rev Pharmacol Toxicol 17: 149PubMedCrossRefGoogle Scholar
  15. 15.
    Fleckenstein G, Fleckenstein A (1980) Calcium-Antagonismus, ein Grundprinzip der Vasodilatation. In: Fleckenstein A, Roskamm H (Hrsg) Calcium-Antagonismus. Springer, Berlin Heidelberg New York, S 191Google Scholar
  16. 16.
    Gould BA, Mann S, Kieso H, Subramanian VB, Raftery EB (1982) The 24-hour ambulatory blood pressure profile with verapamil. Circulation 65: 22PubMedCrossRefGoogle Scholar
  17. 17.
    Guazzi M, Olivari MT, Polese A et al. (1977) Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther 22: 528PubMedGoogle Scholar
  18. 18.
    Guazzi MD, Fiorentini C, Olivari MT, Bartorelli A, Necchi G, Polese A (1980) Short- and long-term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension. Circulation 61: 913PubMedGoogle Scholar
  19. 19.
    Henry PD (1980) Comparative pharmacology of calzium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 46: 1047PubMedCrossRefGoogle Scholar
  20. 20.
    Hulthén L, Bolli P, Amann FW, Kiowski W, Bühler FR (1982) Calcium channel blockade with verapamil induces enhanced vasodilatation in essential hypertension. Hypertension 4: 2–26Google Scholar
  21. 21.
    Kiowski W, Bertel O, Erne P, Hulthin UL, Bolli P, Ritz R, Bühler FR (im Druck) Hemodynamic and reflex mechanism of acute and chronic antihypertensive therapy with the calcium channel blocker nifedipine. HypertensionGoogle Scholar
  22. 22.
    Klein W (1981) Ergebnisse einer Vergleichsuntersuchung zwischen Nifedipin und Diltiazem bei essentieller arterieller Hypertonie. Fortschr Med 99: 1812Google Scholar
  23. 23.
    Kohno K, Takeuchi Y, Etoh A, Noda K (1977) Pharmacokinetics and bioavailability of diltiazem (CRD-401) in dog. Arzneimittelforsch 27: 1424PubMedGoogle Scholar
  24. 24.
    Lederballe-Pedersen O, Mikkelsen E (1978) Acute and chronic effects of nifedipine in arterial hypertension. Eur J Clin Pharmacol 14: 375CrossRefGoogle Scholar
  25. 25.
    Lederballe-Pedersen O, Mikkelsen E, Christensen NJ, Kornerup HJ, Pedersen EB (1979) Effect of nifedipine on plasma renin aldosterone and catecholamines in arterial hypertension. Eur J Clin Pharmacol 15: 235CrossRefGoogle Scholar
  26. 26.
    Lederballe-Pedersen O, Christensen CK, Mikkelsen E, Rämsch KD (1980) Relation between the antihypertensive effect and steadystate plasma concentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent. Eur J Clin Pharmacol 18: 287PubMedCrossRefGoogle Scholar
  27. 27.
    Leonetti G, Sala C, Bianchini C, Terzoli L, Zanchetti A (1980) Antihypertensive and renal effects of orally administered verapamil. Eur J Clin Pharmacol 18: 375PubMedCrossRefGoogle Scholar
  28. 28.
    Leonetti G, Pasotti C, Ferrari GP, Zanchetti A (1981) Double-blind comparison of the antihypertensive effects of verapamil and propranolol. In: Zanchetti A, Krikler DM (eds) Calcium antagonism in cardiovascular therapy. Excerpta Medica, Amsterdam Oxford Princeton, p 260Google Scholar
  29. 29.
    Lewis GRJ, Morley KD, Lewis BM (1978) The treatment of hypertension with verapamil. NZ Med J 87: 351Google Scholar
  30. 30.
    Lydtin H, Lohmöller G, Lohmöller R, Walter I (1975) Hemodynamic studies on nifedipine in man. In: Hashimoto K, Kimura E, Kobayashi T (eds) I st International Nifedipine Symposium. University of Tokyo Press, Tokyo, p 97Google Scholar
  31. 31.
    Maeda K, Takasugi T, Isukano Y, Tanaka Y, Shiota K (1981) Clinical study on the hypotensive effect of diltiazem hydrochloride. Int J Clin Pharmacol 19: 47Google Scholar
  32. 32.
    Maehashi S, Kawamura T, Sato M, Imamura A (1978) Hypotensive effect of long-term diltiazem therapy in essential hypertension. Mod Clin Med 20: 1871Google Scholar
  33. 33.
    Magometschnigg D, Pichler M (1981) Effective and safe treatment of hypertensive crisis with nifedipine. Am J Cardiol 47: 469CrossRefGoogle Scholar
  34. 34.
    Moreselli PL, Rovel V, Mitchard M, Durand A, Gomeni R, Laribaud J (1979) Pharmacokinetics and metabolism of diltiazem in man (observations on healthy volunteers and angina pectoris patients). In: Bing RJ (ed) Diltiazem Hakone Symposium ’78. Excerpta Medica, Amsterdam Princeton, p 152Google Scholar
  35. 35.
    Muiesan G, Agabiti-Rosei E, Alicandri C et al. (1981) Influence of verapamil on catecholamines, renin and aldosterone in essential hypertensive patients. In: Zanchetti A, Krikler DM (eds) Calcium antagonism in cardiovascular therapy. Excerpta Medica, Amsterdam Oxford Princeton, p 238Google Scholar
  36. 36.
    Olivari MT, Bartorelli C, Poles A et al. (1979) Treatment of hypertension with nifedipine, a calcium antagonist drug. Circulation 59: 1056PubMedGoogle Scholar
  37. 37.
    Pedersen OL (1978) Does verapamil have a clinically significant anti-hypertensive effect? Eur J Clin Pharmacol 13: 21PubMedCrossRefGoogle Scholar
  38. 38.
    Pedersen OL, Christensen NJ, Ramsch KD (1980) Comparison of acute effects of nifedipine in normotensive and hypertensive man. J Cardiovasc Pharmacol 2: 357CrossRefGoogle Scholar
  39. 39.
    Piepho RW, Bloedow DC, Lacz JP et al. (1982) Pharmacokinetics of diltiazem in selected animal spezies and human beings. Am J Cardiol 49: 525PubMedCrossRefGoogle Scholar
  40. 40.
    Polese A, Fiorentini C, Olivari MT, Guazzi MD (1979) Clinical use of a calcium antagonistic agent (nifedipine) in acute pulmonary edema. Am J Med 66: 825PubMedCrossRefGoogle Scholar
  41. 41.
    Robinson BF, Dobbs RH, Kelsey CR (1980) Effects of nifedipine on resistance vessels, arteries and veins in man. Br J Clin Pharmacol 10: 433PubMedGoogle Scholar
  42. 42.
    Rosenthal M (1982) Diltiazem in der Therapie der Hochdruckkrise. In: Bender F, Greeff K (Hrsg) Calciumantagonisten zur Behandlung der Angina pectoris, Hypertonie und Arrhythmie. Excerpta Medica, Amsterdam Oxford Princeton, p 227Google Scholar
  43. 43.
    Sawada M, Tanabe Y (1978) The hypotensive effect of diltiazem hydrochloride. Mod Clin Med 20: 1251Google Scholar
  44. 44.
    Singh B, Ellrodt G, Peter CT (1978) Verapamil: a review of its pharmacological properties and therapeutic use. Drugs 15: 169PubMedCrossRefGoogle Scholar
  45. 45.
    Spies HF, Schulz W, Werner H et al. (1980) Einfluß der Calciumantagonisten Verapamil, Nifedipin und Fendilin auf Blutdruck und Herzfrequenz. In: Fleckenstein A, Roskamm H (Hrsg) Calcium-Antagonismus. Springer, Berlin Heidelberg New York, S 252Google Scholar
  46. 46.
    Yorifuji S, Kawai Y, Arami S et al. (1979) Hypertensive effect of diltiazem hydrochloride in patients with essential hypertension. J Adult Dis 9: 893Google Scholar

Literatur: Prazosin

  1. 1.
    Antani JA (1979) Prazosin in hypertension with heart failure. J Cardiovasc Pharmacol 1: 56Google Scholar
  2. 2.
    Awan NA, Miller RR, Maxwell K, Mason DT (1978) Effects of prazosin of forearm resistance and capacitance vessels. Clin Pharmacol Ther 22: 79Google Scholar
  3. 3.
    Awan NA, Miller RR, Maxwell KS et al. (1978) Development of systemic vasodilator tolerance to prazosin with chronic use of the agent in ambulatory therapy of severe congestive heart failure. Am J Cardiol 41: 367CrossRefGoogle Scholar
  4. 4.
    Awan NA, Miller RR, Miller MP et al. (1978) Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure: balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output. Am J Med 65: 146PubMedCrossRefGoogle Scholar
  5. 5.
    Bateman DN, Hobbs DC, Twomey TM, Stevens EA, Rawlins MD (1979) Prazosin, pharmacokinetics and concentration effect. Eur J Clin Pharmacol 16: 177PubMedCrossRefGoogle Scholar
  6. 6.
    Bolli P, Wood AJ, Phelan EL et al. (1975) Prazosin preliminary clinical and pharmacological observations. Clin Sci Mol Med [Suppl 2] 48: 177Google Scholar
  7. 7.
    Brogden RN, Heel RC, Speight TM, Avery GS (1977) Prazosin: A review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14: 163PubMedCrossRefGoogle Scholar
  8. 8.
    Cambridge D, Davey MJ, Massingham R (1977) Prazosin, a selective antagonist of post-synaptic a-adrenoceptors. Br J Pharmacol 59: 514Google Scholar
  9. 9.
    Curtis JR, Bateman FJA (1975) Use of prazosin in management of hypertension in patients with chronic renal failure and in renal transplant recipients. Br Med J IV: 432CrossRefGoogle Scholar
  10. 10.
    Flouvat B, Le Roux E, Safar M (1979) Pharmacokinetic study of prazosin in man: In: Rawlins MD, Geyer G, Bleifeld W (eds) Proceedings of the European Symposium on Prazosin. Excerpta Medica, Amsterdam, p 28Google Scholar
  11. 11.
    Graham RM, Mulvithill-Wilson J (1980) Clinical pharmacology of prazosin used alone or in combination in the therapy of hypertension. J Cardiovasc Pharmacol [Suppl 3] 2: 387CrossRefGoogle Scholar
  12. 12.
    Graham RM, Pettinger WA (1979) Drug therapy: Prazosin. N Engl J Med 300: 232PubMedCrossRefGoogle Scholar
  13. 13.
    Graham RM, Thornell IR, Gain JM et al. (1976) Prazosin: The first-dose phenomenon. Br Med J II: 1293CrossRefGoogle Scholar
  14. 14.
    Graham RM, Oates HF, Stoker LM et al. (1977) Alpha-blocking action of the antihypertensive agent, prazosin. J Pharmacol Exp Ther 201: 747PubMedGoogle Scholar
  15. 15.
    Hayes JM, Graham RM, O’Connell BP et al. (1976) Experience with prazosin in the treatment of patients with severe hypertension. Med J Aust 1: 562PubMedGoogle Scholar
  16. 16.
    Hobbs DC, Twomey TM, Palmer RF (1978) Pharmacokinetics of prazosin in man. J Clin Pharmacol 18: 402PubMedGoogle Scholar
  17. 17.
    Hua ASP, Macdonald IM, Myer JB, Kincaid-Smith P (1976) Studies with prazosin. A new effective hypotensive agent. 1. Open clinical study of prazosin in combination with other antihypertensive agents. Med J Aust 1: 559PubMedGoogle Scholar
  18. 18.
    Kuokkanen K, Mattila MJ (1979) Antihypertensive effect of prazosin in combination with methyldopa, clonidine or propranolol. Ann Clin Res 11: 18PubMedGoogle Scholar
  19. 19.
    Lowenstein J, Steele JM Jr (1978) Prazosin. Am Heart J 95: 262PubMedCrossRefGoogle Scholar
  20. 20.
    Lowenstein J, Steele JM Jr (1979) Prazosin: Mechanism of action and role in antihypertensive therapy. Cardiovasc Med 4: 885Google Scholar
  21. 21.
    Lund-Johansen P (1974) Hemodynamic changes at rest and during exercise in long-term prazosin therapy of essential hypertension. In: Cotton DWK (ed) Prazosin: Evaluation of a new antihypertensive agent. Excerpta Medica, Amsterdam, p 43Google Scholar
  22. 22.
    Marshall AJ, Barritt DW, Pocock J et al. (1977) Evaluation of beta blockade, bendrofluazide and prazosin in severe hypertension. Lancet I: 781Google Scholar
  23. 23.
    McMahon G (1978) Management of essential hypertension. Futura, New YorkGoogle Scholar
  24. 24.
    Miller R, Awan NA, Maxwell KS, Mason DT (1977) Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med 297: 303PubMedCrossRefGoogle Scholar
  25. 25.
    Oates HE, Graham RM, Stoker LM et al. (1976) Haemodynamic effects of prazosin. Arch Int Pharmacodyn Ther 224: 239PubMedGoogle Scholar
  26. 26.
    Oates HF, Graham RM, Stokes GS (1977) Mechanism of the hypotensive action of prazosin. Arch Int Pharmacodyn Ther 227: 41PubMedGoogle Scholar
  27. 27.
    Okun R, Maxwell M (1979) Long-term antihypertensive therapy with prazosin plus a diuretic. J Cardiovasc Pharmacol 1: 21Google Scholar
  28. 28.
    Pitts NE (1974) The clinical evaluation of prazosin hydrochloride, a new antihypertensive agent. In: Cotton DWK (ed) Prazosin: Evaluation of a new antihypertensive agent. Excerpta Medica, Amsterdam, p 149Google Scholar
  29. 29.
    Rosendoff D (1976) Prazosin: Severe side effects are dose-dependent. Br Med J II: 508CrossRefGoogle Scholar
  30. 30.
    Schriger A, Sheps SG (1977) Prazosin — new hypertensive agent: A doubleblind crossover study in the treatment of hypertension. JAMA 237: 989CrossRefGoogle Scholar
  31. 31.
    Scivoletto R, Toledo AJO, Gomes da Silva AC et al. (1976) Mechanism of the hypotensive effect of prazosin. Arc Int Pharmacodyn Ther 223: 333Google Scholar
  32. 32.
    Stokes GS, Oates HF (1978) Prazosin: New alpha-adrenergic blocking agent in treatment of hypertension. Cardiovasc Med 3: 41Google Scholar
  33. 33.
    Stokes GS, Oates HF (1980) Prazosin: An alpha-adrenergic blocking agent in the treatment of hypertension. In: Laragh J (ed) Topics in hypertension. Medical Books, Lochem, p 445Google Scholar
  34. 34.
    Stokes GS, Weber MA (1974) Prazosin: Preliminary report and comparative studies with other antihypertensive agents. Br Med J II: 298CrossRefGoogle Scholar
  35. 35.
    Stokes GS, Gain JM, Mahony JF et al. (1977) Long-term use of prazosin in combination or alone for treating hypertension. Med J Aust 2: 13PubMedGoogle Scholar
  36. 36.
    Stokes GS, Monaghan J, Frost G, MacCarthy P (1979) Analyzing responsiveness to prazosin in renal failure: New pharmacodynamic approach. Clin Sci 57: 383Google Scholar
  37. 37.
    Taylor JA, Twomey TM, Schach Von Wittenau M (1977) The metabolic fate of prazosin. Xenobiotica 7: 357PubMedCrossRefGoogle Scholar
  38. 38.
    Van Zweiten PA, Lam E, Timmermans PM (1978) The interaction between prazosin and clonidine. Clin Sci 5: 2598Google Scholar

Literatur: Phentolamin und Phenoxybenzamin

  1. 1.
    Baylis PH (1974) Reaction to phenoxybenzamine. Lancet II: 1514CrossRefGoogle Scholar
  2. 2.
    Crout JR, Brown BR (1969) Anesthetic management of pheochromocytoma: the value of phenoxybenzamine. Anesthesiology 30: 29CrossRefGoogle Scholar
  3. 3.
    Das PK, Parratt JR (1971) Myocardial and haemodynamic effects of phentolamine. Br J Pharmacol 41: 437PubMedGoogle Scholar
  4. 4.
    Engelman K, Sjoerdsma A (1964) Chronic medical therapy for pheochromocytoma: a report of four cases. Ann Intern Med 61: 229PubMedGoogle Scholar
  5. 5.
    Manger WM, Gifford RW (1977) Pheochromocytoma. Springer, Berlin Heidelberg New York, p 304CrossRefGoogle Scholar
  6. 6.
    Nickerson M, Collier B (1975) Alpha-adrenergic blocking agents. In: Goodman L, Gilman A (eds) The pharmacoligical basis of therapeutics, 5th edn. p 533 Macmillan Publishing Co. New YorkGoogle Scholar
  7. 7.
    Page LB, Raker JW, Berberich FR (1969) Pheochromocytoma with predominant epinephrine secretion. Am J Med 47: 648PubMedCrossRefGoogle Scholar
  8. 8.
    Ross EJ, Prichard BNC, Kaufman L et al. (1967) Preoperative and operative management of patients with pheochromocytoma. Br Med J I: 191CrossRefGoogle Scholar
  9. 9.
    Taylor SH, Sutherland GR, Mackenzie GJ et al. (1965) The circulatory effects of phentolamine in man with particular respect to changes in forearm blood flow. Clin Sci 28: 265PubMedGoogle Scholar
  10. 10.
    Wyse DG, Beck L (1972) Phenoxybenzamine blockade of neural and exogenous noradrenaline. J Pharm Pharmacol 24: 478PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Abe K, Itoh T, Imai Y et al. (1980) Implication of endogenous prostaglandin system in the anti-hypertensive effect of captopril, SQ-14225, in low renin hypertension. Jpn Circ J 44: 422–425PubMedCrossRefGoogle Scholar
  2. 2.
    Brunner HR, Wauters J-P, McKinstry D, Waeber B, Turini G, Gavras H (1978) Inappropriate renin secretion unmasked by Captopril (SQ 14225) in hypertension of chronic renal failure. Lancet II: 704–707CrossRefGoogle Scholar
  3. 3.
    Brunner, HR, Gavras H, Waeber B, Textor SC, Turini GA, Wauters JP, (1980) Clinical use of an orally acting converting enzyme inhibitor: Captopril. Hypertension 2: 558–566PubMedGoogle Scholar
  4. 4.
    Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN (1978) Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14225, Captopril) in hypertensive patients. Prog Cardiovasc Dis 21: 195–205PubMedCrossRefGoogle Scholar
  5. 5.
    Cody RJ, Tarazi RC, Bravo EL, Fouad FM (1978) Haemodynamics of orally active converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci 55: 453–459Google Scholar
  6. 6.
    Editorial (1980) Captopril: Benefits and risks in severe hypertension. Lancet II 129–130Google Scholar
  7. 7.
    Erdös EG (1977) The angiotensin I converting enzyme. Fed Proc 36: 1760–1765PubMedGoogle Scholar
  8. 8.
    Ferguson, RK, Turinin GA, Brunner HR, Gavras H, McKinstry D (1977) A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet I: 775CrossRefGoogle Scholar
  9. 9.
    Gavras H, Brunner HR, Turini GA et al. (1978) Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 298: 991–995PubMedCrossRefGoogle Scholar
  10. 10.
    Gavras H, Waeber B, Gavras I, Biollaz J, Brunner HR, Davies RO (1981) Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor „MK-421“. Lancet II: 543–547CrossRefGoogle Scholar
  11. 11.
    Heel RC, Brogden RN, Speight TM, Avery GS (1980) Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–452PubMedCrossRefGoogle Scholar
  12. 12.
    Hornych A, Safar M, Gitelman R, Simon A, Bariety J, Milliez P (1980) The effect of captopril (C) on plasma and urinary prostaglandins (PG) in essential hypertension. World Conference on Clinical Pharmacology and Therapeutics [Abstr. 0410], LondonGoogle Scholar
  13. 13.
    Johnston CI, McGrath BP, Millar JA, Matthews PG (1979) Long-term effects of captopril (SQ 14225) on bloodpressure and hormone levels in essential hypertension. Lancet II: 493–495CrossRefGoogle Scholar
  14. 14.
    Koike H, Ito K, Miyamoto M, Nishino H (1980) Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ 14225) on haemodynamics and circulating blood volume in SHR. Hypertension 2: 299–303PubMedGoogle Scholar
  15. 15.
    Lederle RM, Klaus D, Braun B (1980) Captopril bei essentieller Hypertonie. Dtsch. Med Wochenschr 105: 1307–1312PubMedCrossRefGoogle Scholar
  16. 16.
    Lijnen P, Fagard R, Staessen J, Verschueren LJ, Amery A (1980) Dose response in captopril therapy of hypertension. Clin Pharmacol Ther 28: 310–315PubMedCrossRefGoogle Scholar
  17. 17.
    Millar JA, Johnston CI (1979) Sequential changes in circulating levels of angiotensin I and II, renin and bradykinin after captopril. Med J Aust 2 (Nop 8, Suppl): 15–17Google Scholar
  18. 18.
    Murthy VS, Waldron TL, Goldberg ME (1978) The mechanism of bradykinin potentiation after inhibition of angiotensin — converting enzyme by SQ 14225 in conscious rabbits. Circ Res 43: 140–144Google Scholar
  19. 19.
    Overlack A, Stumpe KO, Heck I, Krück F (1980) Neues Prinzip in der Langzeitbehandlung der essentiellen Hypertension. Angiotensin-Converting-Enzym-Hemmung. Dtsch Med Wochenschr 105: 505–509PubMedCrossRefGoogle Scholar
  20. 20.
    Overlack A, Stumpe KO, Kühnert M, Kolloch R, Ressel C, Heck I, Krück F (1981) Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition. Klin Wochenschr 59: 69–74PubMedCrossRefGoogle Scholar
  21. 21.
    Rubin B, Antonaccio MJ (1980) Captopril. In: Scriabine A (ed) Pharmacology of antihypertensive drugs. Raven, New York, pp 21–41Google Scholar
  22. 22.
    Staessen J, Fagard R, Lijnen P, Amery A (1980) Captopril and agranulocytosis. Lancet I: 926–927CrossRefGoogle Scholar
  23. 23.
    Studer A, Lüscher T, Siegenthaler W, Vetter W (1981) Captopril in various forms of severe therapy-resistant hypertension. Klin Wochenschr 59: 59–67PubMedCrossRefGoogle Scholar
  24. 24.
    Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ (1980) Captopril-induced changes in prostaglandin production. Relationship to vascular responses in normal man. J Clin Invest 65: 1257–1264PubMedCrossRefGoogle Scholar
  25. 25.
    Thibonnier M, Soto ME, Menard J, Aldiger JC, Corvol P, Milliez P (1981) Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril. Eur J Clin Invest 11: 449–453PubMedCrossRefGoogle Scholar
  26. 26.
    Thurston H, Swales JD (1978) Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor. Circ Res 42: 588–592PubMedGoogle Scholar
  27. 27.
    Turini GA, Brunner HR, Gibric M, Waeber B, Gavras H (1979) Improvement of chronic congestive heart failure by oral captopril. Lancet I: 1213CrossRefGoogle Scholar
  28. 28.
    Waeber B, Brunner HR, Brunner DB, Curtet A-L, Turini GA, Gavras H (1980) Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 2: 236–242PubMedGoogle Scholar
  29. 29.
    Warren SE, O’Connor DT (1981) Hyperkaliämie nach Behandlung mit Captopril. JAMA I: 75–76Google Scholar

Literatur

  1. 1.
    Gaffney TE, Sigell LT, Mohammed S Atkinson AJ (1969) The clinical pharmacology of antihypertensive drugs. Prog Cardiovasc Dis 12: 52–71PubMedCrossRefGoogle Scholar
  2. 2.
    Kewitz H, Jesdinsky HJ, Schröter P-M, Lindtner E (1977) Reserpine and breast cancer in women in Germany. Eur J Clin Pharmacol 11: 79–83PubMedCrossRefGoogle Scholar
  3. 3.
    Munson WM, Jenicek JA (1962) Effect of anesthetic agents on patients receiving reserpine therapy. Anesthesiology 23: 741–746PubMedCrossRefGoogle Scholar
  4. 4.
    Pare CMB (1973) Psychiatric complications of everyday drugs. Practitioner 210: 120–126PubMedGoogle Scholar
  5. 5.
    Sulser F, Bickel MH, Brodie BB (1964) The action of desmethylimipranine in counteracting sedation and cholinergic effects of reserpin-like drugs. J Pharmacol Exp Ther 144: 321–330Google Scholar

Literatur

  1. 1.
    Dollery CT, Jerie P (eds) (1980) Proceedings of the symposium on centrally acting drugs in modern antihypertensive therapy (Guanfacin). Br J Clin Pharmacol 10 (Suppl 1): 1s–208sGoogle Scholar
  2. 2.
    Gold MS, Pottash AC, Sweeney DR, Kleber HD (1980) Opiate withdrawal using clonidine — A safe, effective, and rapid nonopiate treatment. J Am Med Assoc 243: 343–346CrossRefGoogle Scholar
  3. 3.
    Haeusler G (1973) Activation of the central pathway of the baroreceptor reflex, a possible mechanism of the hypothensive action of clonidine. Naunyn Schmiedebergs Arch Pharmacol 278: 231–246PubMedCrossRefGoogle Scholar
  4. 4.
    Kobinger W (1978) Central alpha-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 81: 39–100PubMedCrossRefGoogle Scholar
  5. 5.
    Kobinger W, Pichler L (1976) Centrally induced reduction in sympathetic tone — a postsynaptic alpha-adrenergic stimulation action of imidazolines. Eur J Pharmacol 40: 311–320PubMedCrossRefGoogle Scholar
  6. 6.
    Mroczek WJ, Davidov M, Finnerty FA (1973) Intravenous clonidine in hypertensive patients. Clin Pharmacol Ther 14: 847–851PubMedGoogle Scholar
  7. 7.
    Schmitt H (1977) The pharmacology of Clonidine and related products. In: Gross F (ed) Antihypertensive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 39, pp 299–396)Google Scholar
  8. 8.
    Wilber JA (ed) (1980) Clonidine. J Cardiovasc Pharmacol 2: [Suppl 1]: 1–89Google Scholar

Literatur

  1. 1.
    Altura BM (1975) Pharmacological effect of alpha-methyldopa, alpha-methylnoradrenaline, and octapamine on rat arteriolar, arterial and terminal vascular smooth muscle. Circ Res 36 [Suppl I]: 223–246Google Scholar
  2. 2.
    Henning M, Rubenson A (1971) Evidence that the hypotensive action of methyldopa is mediated by central actions of methylnoradrenaline. J Pharm Pharmacol 23: 407–411PubMedCrossRefGoogle Scholar
  3. 3.
    Kopin IJ (1968) False adrenergic transmitters Ann Rev Pharmacol 8: 337–394CrossRefGoogle Scholar
  4. 4.
    Zwieten PA van (1975) Antihypertensive drugs with a central action. In: Progress in pharmacology, vol 1. Fischer, Stuttgart, pp 1–63Google Scholar

Literatur

  1. 1.
    Chang CC, Costa E, Brodie BB (1965) Interaction of guanethidine with adrenergic neurons. J Pharmacol Exp Ther 147: 303–312PubMedGoogle Scholar
  2. 2.
    Mitchell JR, Cavanaugh JH, Arias L, Oates JA (1970) Guanethidine and related agents. Antagonism by drugs which inhit the norepinephrine pump in man. J Clin Invest 49: 1596–1604PubMedCrossRefGoogle Scholar
  3. 3.
    Talbot S, Smith AJ (1975) Factors predisposing to postural hypotensive symptoms in the treatment of high blood pressure. Br Heart J 37: 1059–1063PubMedCrossRefGoogle Scholar

Allgemeine Literatur

  1. Goodman LS, Gilman A (1975) The pharmacological basis of therapeutics, 5. edn Mac Millan, New YorkGoogle Scholar
  2. Gross F (ed) (1977) Handbook of experimental pharmacology, vo139, Antihypertensive agents. Springer, Berlin Heidelberg New YorkGoogle Scholar
  3. Harnack GA von Janssen F (1977) Padiatrische Dosistabellen. Deutscher Apotheker-Verlag, StuttgartGoogle Scholar
  4. Mc Mahon FG (1978) Management of essential hypertension. Futura, Mount Kisco New YorkGoogle Scholar
  5. Saller R, Berger T, Ulmer E-M, Hellenbrecht D (1979) Praktische Pharmakologie. Schattauer, Stuttgart New YorkGoogle Scholar
  6. Scheler F, Grone H-J (1980) Hypertonie in K1inik und Praxis. Schattauer, Stuttgart New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • H. Knauf
  • K. O. Stumpe
  • R. Kolloch
  • A. Overlack
  • W. Rascher
  • D. Ganten
  • R. E. Lang
  • Th. Unger

There are no affiliations available

Personalised recommendations